Development of a prediction models for chemotherapy-induced adverse drug reactions: A retrospective observational study using electronic health records

Alejandro, 2013, Predicting acute and persistent neuropathy associated with oxaliplatin, Am. J. Clin. Oncol., 36, 331, 10.1097/COC.0b013e318246b50d Ambinder, 2005, Electronic health records, J Oncol Pract, 1, 57, 10.1200/jop.2005.1.2.57 Bano, 2013, Neurological adverse effects in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX, Chemother Res Pract, 10.1155/2013/379870 Bray, 2016, Acute and chronic cutaneous reactions to ionizing radiation therapy, Dermatol. Ther., 6, 185, 10.1007/s13555-016-0120-y Cascinu, 1997, Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients, Support. Care Cancer, 5, 314, 10.1007/s005200050079 Chopra, 2016, Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey, Indian J. Med. Paediatr. Oncol., 37, 42, 10.4103/0971-5851.177015 de Lima, 2018, Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis, Oral Dis., 24, 207, 10.1111/odi.12771 Dietrich, 2015, Nausea and vomiting, 199 Dranitsaris, 2009, Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical prediction tool. I. Acute nausea and vomiting, J. Support Oncol., 7, W1 Dranitsaris, 2017, The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting, Ann. Oncol., 28, 1260, 10.1093/annonc/mdx100 Fernandez-Rozadilla, 2013, Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration, Pharmacogenomics J., 13, 209, 10.1038/tpj.2012.2 Gobel, 2005, Chemotherapy-induced hypersensitivity reactions, Oncol. Nurs. Forum, 32, 1027, 10.1188/05.ONF.1027-1035 Goldstein, 2017, Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review, J. Am. Med. Inf. Assoc., 24, 198, 10.1093/jamia/ocw042 Heo, 2004, Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy, J. Clin. Pharmacol., 44, 1166, 10.1177/0091270004268321 Hsu, 2019, Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy, Eur. J. Oncol. Nurs., 43, 101670, 10.1016/j.ejon.2019.09.011 Imai, 2020, Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with lung cancer, Jpn. J. Clin. Oncol., 51, 444, 10.1093/jjco/hyaa186 Kacimi, 2013, Clinical-based prediction of side effects in colon cancer chemotherapy, 617 Kamen, 2014, Anticipatory nausea and vomiting due to chemotherapy, Eur. J. Pharmacol., 722, 172, 10.1016/j.ejphar.2013.09.071 Kearney, 2009, Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity, Support. Care Cancer, 17, 437, 10.1007/s00520-008-0515-0 Keefe, 2014, Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy, Cancer Chemother. Pharmacol., 74, 675, 10.1007/s00280-014-2526-5 Kim, 2009, Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review, Oncology, 76, 231, 10.1159/000205263 Lau, 2004, The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you?, Support. Care Cancer, 12, 626 Lee, 2009, Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents, Ann. Allergy Asthma Immunol., 102, 179, 10.1016/S1081-1206(10)60078-6 Mazzocco, 2011, A side-effects mapping model in patients with lung, colorectal and breast cancer receiving chemotherapy, 34 McQuade, 2016, Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments, Front. Pharmacol., 7, 414, 10.3389/fphar.2016.00414 Molassiotis, 2008, Understanding the concept of chemotherapy-related nausea: the patient experience, Eur. J. Cancer Care, 17, 444, 10.1111/j.1365-2354.2007.00872.x Mosa, 2020, Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review, Front. Pharmacol., 11, 10.3389/fphar.2020.00329 Parel, 2014, Hypersensitivity to oxaliplatin: clinical features and risk factors, BMC Pharmacol Toxicol, 15, 1, 10.1186/2050-6511-15-1 Park, 2013, An introduction to logistic regression: from basic concepts to interpretation with particular attention to nursing domain, J. Korean Acad. Nurs., 43, 154, 10.4040/jkan.2013.43.2.154 Pearce, 2017, Incidence and severity of self-reported chemotherapy side effects in routine care: a prospective cohort study, PLoS One, 12, 10.1371/journal.pone.0184360 Petrella, 2009, Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool. II Delayed nausea and vomiting, J. Support Oncol., 7, W9 Ravì, 2017, Deep learning for health informatics, IEEE J. Biomed. Health Inform, 21, 4, 10.1109/JBHI.2016.2636665 Sendo, 2005, Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy, Cancer Chemother. Pharmacol., 56, 91, 10.1007/s00280-004-0924-9 Simmons, 2012, Clinical management of pain in advanced lung cancer, Clin. Med. Insights Oncol., 6, 331, 10.4137/CMO.S8360 Song, 2015, Decision tree methods: applications for classification and prediction, Shanghai Arch. Psychiatry, 27, 130 Soyemi, 2015 Stein, 2010, Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management, Ther. Adv. Med. Oncol., 2, 51, 10.1177/1758834009355164 Tu, 1996, Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes, J. Clin. Epidemiol., 49, 1225, 10.1016/S0895-4356(96)00002-9 Wellstein, 2018, General principles in the pharmacotherapy of cancer, 1161 Wuketich, 2012, Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors, Support. Care Cancer, 20, 175, 10.1007/s00520-011-1107-y